BioCardia completed enrollment and dosing in the low-dose cohort of its CardiALLO™ Phase I/II trial. This trial investigates allogeneic mesenchymal stem cell (MSC) therapy for patients with ischemic heart failure and reduced ejection fraction (HFrEF) who also exhibit elevated markers of heart stress and systemic inflammation. The trial incorporates the Morph DNA steerable guide for enhanced cell delivery.
This trial is particularly important because it addresses a patient population with limited treatment options despite receiving standard care. The focus on patients with specific biomarkers (heart stress and inflammation) suggests a precision medicine approach, potentially leading to better patient outcomes and a more efficient drug development process. Utilizing a steerable guide for cell delivery further refines the procedure, potentially improving efficacy and safety.
The Phase I portion of the trial includes a nine-patient dose escalation cohort, administering 20 million, 100 million, and 200 million cells. A Data Safety Monitoring Board (DSMB) will review safety data after each dose cohort. The “off-the-shelf” nature of the allogeneic MSCs offers logistical advantages over autologous therapies. BioCardia’s manufacturing process for these cells is designed for commercial scalability. Following the Phase I safety evaluation, a randomized, double-blinded, placebo-controlled Phase II cohort will assess efficacy in thirty patients.
The completion of low-dose cohort enrollment marks a significant step in the development of the CardiALLO therapy. Positive safety and efficacy data could pave the way for larger pivotal trials and potential conditional approval in Japan. This progress also strengthens BioCardia’s position in the cell therapy space, complementing its autologous cell therapy program, CardiAMP. Furthermore, the established allogeneic MSC manufacturing platform may open doors for partnerships in other therapeutic areas, such as acute respiratory distress syndrome.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
